It is reported that IFN and its therapeutic applications have serious side effects, such as the lethal graft-versus-host disease effect of Allo-SCT and resistance to STI-571 in CML treatment. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.